Lakewood-Amedex Biotherapeutics Inc. (LABT) Income Statement
LABT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLABT revenue and net income
LABT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LABT quarterly EPS vs estimates
Lakewood-Amedex Biotherapeutics beat the analyst EPS estimate in 0 of the last 1 quarters. Next report: November 12, 2026 (estimate $0.81).
LABT income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research & development | $1.3M | $2.1M | $5.5M |
| Sales, general & admin | $2.5M | $1.9M | $3.1M |
| Total operating expenses | $3.8M | $4.0M | $8.6M |
| Operating income | −$3.8M | −$4.0M | −$8.6M |
| Interest income | $25,614 | $142,596 | $360,122 |
| Interest expense | $100,881 | $5,000 | $10,000 |
| Income before taxes | −$3.8M | −$4.9M | −$8.3M |
| Net income | −$3.8M | −$4.9M | −$8.3M |
| EBITDA | −$3.6M | −$4.7M | −$8.2M |
| EPS (diluted) | −$20.14 | −$3.48 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | $30,290 | — | — | — | — | — | — | — |
| Gross profit | — | — | −$30,290 | — | — | — | — | — | — | — |
| Research & development | $503,020 | $182,147 | $185,730 | $752,931 | $146,901 | $169,703 | $432,594 | $540,948 | $548,482 | $581,342 |
| Sales, general & admin | $3.3M | $703,444 | $525,172 | $1.1M | $489,325 | $371,747 | $428,424 | $370,558 | $560,242 | $557,931 |
| Total operating expenses | $3.8M | $886,750 | $712,060 | $1.9M | $637,384 | $542,609 | $862,176 | $912,913 | $1.1M | $1.1M |
| Operating income | −$3.8M | −$886,750 | −$712,060 | −$1.9M | −$637,384 | −$542,609 | −$862,176 | −$912,913 | −$1.1M | −$1.1M |
| Interest income | $28,285 | $1,078 | $4,950 | $10,966 | $5,390 | $4,307 | $7,637 | — | — | — |
| Interest expense | $10,633 | $38,219 | $37,808 | $37,808 | $18,559 | $1,315 | $0 | — | — | — |
| Income before taxes | −$3.8M | −$923,291 | −$744,918 | −$1.9M | −$655,943 | −$539,617 | −$854,539 | −$1.9M | −$1.1M | −$1.0M |
| Net income | −$3.8M | −$923,291 | −$744,918 | −$1.9M | −$655,943 | −$539,617 | −$854,539 | −$1.9M | −$1.1M | −$1.0M |
| EBITDA | −$3.7M | −$856,858 | −$681,770 | −$1.8M | −$636,226 | −$508,601 | −$825,028 | −$911,506 | −$1.1M | −$1.1M |
| EPS (diluted) | −$2.75 | −$1.32 | — | — | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LABT's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LABT financial results
Lakewood-Amedex Biotherapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $3.8 million. Diluted earnings per share came to −$20.14.
See the LABT stock overview for the latest quote and news, or the LABT chart for price history and technical indicators.
LABT income statement FAQ
Does Lakewood-Amedex Biotherapeutics have revenue?
Lakewood-Amedex Biotherapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Lakewood-Amedex Biotherapeutics profitable?
No. Lakewood-Amedex Biotherapeutics reported a net loss of $3.8 million in fiscal 2025.
How much does Lakewood-Amedex Biotherapeutics spend on research and development?
Lakewood-Amedex Biotherapeutics spent $1.3 million on research and development in fiscal 2025.
What are Lakewood-Amedex Biotherapeutics's earnings per share?
Lakewood-Amedex Biotherapeutics earned $-20.14 per diluted share in fiscal 2025, compared with $-3.48 a year earlier.
When will Lakewood-Amedex Biotherapeutics report its next earnings?
Lakewood-Amedex Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Lakewood-Amedex Biotherapeutics's fiscal year end?
Lakewood-Amedex Biotherapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.